T-8

Dosage for Cichorium Intybus Whole is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity levels. There is no 'standard' dose for all patients.

Diagnostic Dosing

• Skin Prick Test: One drop of the extract (typically 1:10 or 1:20 w/v) is applied to the skin, followed by a superficial puncture. The result is read after 15 to 20 minutes.
• Intradermal Test: 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 w/v) is injected into the dermis. This is only performed if the prick test is negative.

Therapeutic Dosing (Immunotherapy)

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:10,000 w/v dilution). Injections are given 1-2 times per week, with the dose increasing by 10% to 50% at each visit, provided no significant local or systemic reactions occur.
• Maintenance Phase: Once the 'top dose' or maintenance dose is reached (often 0.5 mL of a 1:10 or 1:20 w/v concentration), the interval between injections is increased to every 2 to 4 weeks. This phase usually continues for 3 to 5 years.

Cichorium Intybus Whole is used in children, but the safety and efficacy depend on the child's age and ability to cooperate with the procedure.

• Children under 5: Generally, immunotherapy is used with caution due to the difficulty in communicating early symptoms of systemic reactions.
• Children 5 and older: Dosing follows the same titration principles as adult dosing, though initial doses may be even more conservative depending on the child's weight and sensitivity.

Renal Impairment

No specific dose adjustments are required for patients with kidney disease, as the extract is not systemically metabolized in a way that significantly impacts renal function. However, the patient's overall health must be stable.

Hepatic Impairment

No dosage adjustments are necessary for patients with liver impairment. The proteins in Cichorium Intybus Whole do not undergo hepatic processing via the CYP450 system.

Elderly Patients

Older adults (over 65) may have a higher risk of cardiovascular complications if a systemic reaction occurs. Healthcare providers may use lower starting doses or slower titration schedules for elderly patients with underlying heart conditions.

Cichorium Intybus Whole is never self-administered. It must be given by a healthcare professional.

• Preparation: The skin (usually the forearm or back) is cleaned with alcohol.
• Observation: After receiving an injection or skin test, the patient must remain in the clinic for at least 30 minutes. Most serious reactions occur within this timeframe.
• Storage: Extracts must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Freezing will denature the proteins and render the extract ineffective.

In immunotherapy, consistency is vital. If a dose is missed:

• 1-2 weeks late: The previous dose may be repeated.
• 3-4 weeks late: The dose may need to be reduced by 50% to ensure safety.
• Over 4 weeks late: The titration may need to be restarted from a much lower concentration.

An overdose of Cichorium Intybus Whole (receiving too much extract or too high a concentration) can lead to a severe systemic allergic reaction or anaphylaxis.

• Signs: Hives, swelling of the throat, wheezing, rapid pulse, or a sharp drop in blood pressure.
• Action: Immediate administration of epinephrine (EpiPen) and emergency medical support is required. If an overdose is suspected during a skin test, the site should be wiped clean immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Ensure your provider is aware of any new medications or health changes between doses.

Most patients receiving Cichorium Intybus Whole for diagnostic testing or immunotherapy will experience some form of local reaction. These are generally not dangerous but indicate the body's immune response to the allergen.

• Local Wheal and Flare: During skin testing, a raised, itchy bump (wheal) surrounded by redness (flare) is expected. This typically peaks at 20 minutes and fades within 2 hours.
• Injection Site Swelling: In immunotherapy, it is common to experience swelling at the site of the injection. This may feel like a firm, warm, and itchy lump under the skin. It can range from the size of a dime to the size of a half-dollar.
• Pruritus (Itching): Intense itching at the site of administration is the most frequently reported symptom. This is caused by the localized release of histamine.
• Erythema: Redness of the skin around the administration site is common and may last for several hours.

These side effects are more generalized and may indicate a mild systemic response to the extract.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter at the injection site. This may be accompanied by significant discomfort and may require a dose adjustment for the next visit.
• Fatigue: Some patients report feeling unusually tired for several hours after receiving an immunotherapy injection.
• Mild Nasal Congestion: A slight 'stuffy nose' or sneezing shortly after the procedure.
• Headache: A dull, throbbing sensation that typically resolves with over-the-counter analgesics.

Rare side effects are often systemic and require close monitoring by the clinical staff.

• Generalized Urticaria (Hives): Itchy welts appearing on parts of the body far from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes, lips, or extremities.
• Vasovagal Reaction: Fainting or lightheadedness, often due to the anxiety of the needle rather than the extract itself.
• Persistent Subcutaneous Nodules: Small, hard lumps at the injection site that may persist for weeks but are generally harmless.

> Warning: Stop taking Cichorium Intybus Whole and call your doctor immediately if you experience any of these symptoms. These may be signs of anaphylaxis, a life-threatening allergic reaction.

• Difficulty Breathing or Wheezing: This indicates bronchospasm (constriction of the airways).
• Tightness in the Chest or Throat: A feeling that the airway is closing or that it is difficult to swallow.
• Rapid or Weak Pulse: Signs of cardiovascular distress or impending shock.
• Dizziness or Loss of Consciousness: Caused by a sudden drop in blood pressure (hypotension).
• Severe Nausea, Vomiting, or Abdominal Cramps: Systemic allergic reactions can affect the gastrointestinal tract.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

Cichorium Intybus Whole is generally not associated with long-term organ toxicity. The primary long-term concern is the development of 'serum sickness-like' reactions, though this is extremely rare with modern, purified extracts. Some patients may develop a long-term sensitivity to other plants in the Asteraceae family due to shared epitopes (protein structures). There is no evidence that chicory extracts cause cancer, infertility, or chronic autoimmune diseases.

According to the FDA-approved labeling for allergenic extracts, including Cichorium Intybus Whole, there is a Black Box Warning regarding the risk of severe systemic reactions.

Summary of Warning: Cichorium Intybus Whole can cause severe life-threatening systemic reactions, including anaphylaxis. Patients with unstable or severe asthma are at a higher risk for fatal reactions. This product must only be administered by physicians who are experienced in the treatment of anaphylaxis and have the necessary equipment (including epinephrine) to manage such emergencies. Patients must be observed for at least 30 minutes following administration.

Report any unusual symptoms to your healthcare provider. Even a mild systemic reaction (like a few hives) must be reported, as it may predict a more severe reaction at the next dose.

Cichorium Intybus Whole is a potent biological agent. Its use is strictly limited to clinical settings. Patients must be in their 'baseline' state of health before receiving an injection. If you are suffering from an acute infection, a fever, or an asthma flare-up, your appointment must be rescheduled. The safety of this extract depends on the body's ability to process the allergen without an over-reactive systemic response.

No FDA black box warnings are specific solely to chicory, but all non-standardized allergenic extracts carry the class-wide warning for anaphylaxis. The warning emphasizes that Cichorium Intybus Whole is not interchangeable with other extracts and that the risk of death exists if administered improperly or to high-risk patients (such as those on beta-blockers or those with uncontrolled asthma).

• Anaphylaxis Risk: This is the primary concern. Anaphylaxis can occur even in patients who have previously tolerated the extract. It is unpredictable and requires immediate intervention with epinephrine.
• Asthma Status: Patients with symptomatic or poorly controlled asthma (FEV1 < 70% of predicted) are at the highest risk for a fatal outcome if a systemic reaction occurs. Asthma must be stable before any injection.
• Cardiovascular Risk: Patients with underlying heart disease may not be able to tolerate the physiological stress of a systemic reaction or the side effects of the epinephrine used to treat it.
• Injection Technique: Inadvertent intravenous injection can cause immediate, severe systemic reactions. The healthcare provider must always 'aspirate' (pull back on the syringe) to ensure no blood enters the needle before injecting the extract.

Patients undergoing treatment with Cichorium Intybus Whole do not typically require routine blood work (like liver or kidney function tests). Instead, monitoring is clinical:

• Wait Time: A mandatory 30-minute post-injection wait time in the clinic.
• Peak Flow Meter: Asthma patients may be asked to perform a peak flow test before and after the injection to ensure their lung function is stable.
• Symptom Diary: Patients should keep a record of any late-phase reactions (swelling that occurs 6-12 hours later) to report to their doctor.

Most patients can drive after the 30-minute observation period. However, if you experience dizziness, fatigue, or a mild systemic reaction, you should not drive or operate heavy machinery until the symptoms have completely resolved. If epinephrine is administered, you should be transported to an emergency room and should not drive.

Alcohol should be avoided for several hours before and after receiving Cichorium Intybus Whole. Alcohol causes vasodilation (opening of blood vessels), which can increase the rate of allergen absorption and potentially trigger or worsen a systemic reaction.

Stopping Cichorium Intybus Whole immunotherapy does not cause a 'withdrawal' syndrome like some medications. However, if the treatment is stopped before the recommended 3-5 year course, the allergic symptoms are likely to return. If you decide to stop, discuss a tapering or alternative management plan with your allergist.

> Important: Discuss all your medical conditions with your healthcare provider before starting Cichorium Intybus Whole. Be sure to mention if you have started any new heart or blood pressure medications.

There are no drugs that are strictly 'contraindicated' in the sense that they cause a chemical reaction with the extract. However, certain drugs make the management of a side effect impossible or dangerous:

• Beta-Blockers (e.g., Propranolol, Atenolol): These are the most significant concern. If a patient on beta-blockers has an anaphylactic reaction to Cichorium Intybus Whole, the epinephrine used to save their life may not work. Beta-blockers block the receptors that epinephrine needs to stimulate to open the airways and raise blood pressure. This can lead to 'refractory' (untreatable) anaphylaxis.

• ACE Inhibitors (e.g., Lisinopril): These medications may increase the risk of severe systemic reactions or interfere with the body's compensatory mechanisms during an allergic reaction.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine, leading to dangerously high blood pressure if an emergency occurs.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the cardiovascular effects of epinephrine administered during a reaction.

• Antihistamines (e.g., Cetirizine, Loratadine, Diphenhydramine): These do not cause a dangerous reaction, but they interfere with diagnostic testing. Antihistamines block the H1 receptors, preventing the 'wheal and flare' from appearing even if the patient is allergic. Patients must stop taking antihistamines for 3 to 7 days before a skin test.
• H2 Blockers (e.g., Famotidine): These can also mildly suppress skin test results and should be discontinued before diagnostic procedures.
• Topical Steroids: Applying steroid creams to the test site can suppress the local immune response and lead to a false-negative result.

• Alcohol: As mentioned, alcohol can increase blood flow to the skin and accelerate the absorption of the allergen, increasing the risk of a systemic reaction.
• Cross-Reactive Foods: Patients allergic to Cichorium Intybus may experience 'Oral Allergy Syndrome' when eating related foods like endive, radicchio, artichoke, or sunflower seeds. Consuming these foods immediately before a skin test or injection may prime the immune system for a more vigorous reaction.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat allergic reactions, though the clinical significance is low.
• Feverfew/Chamomile: Since these are in the same plant family as chicory (Asteraceae), taking these supplements may increase the baseline level of allergic inflammation in sensitized patients.

Cichorium Intybus Whole does not interfere with standard blood chemistry or hematology tests. However, it will directly affect:

• Skin Prick Tests: Obviously, the extract is the tool for the test.
• In Vitro IgE Testing (ImmunoCAP): While the extract doesn't change the blood test result, clinicians often compare the results of the skin test with the blood test to confirm a diagnosis.

For each major interaction, the management strategy involves either discontinuing the interfering medication (antihistamines) or performing a strict risk-benefit analysis (beta-blockers). In many cases, patients on beta-blockers are switched to an alternative blood pressure medication before starting immunotherapy.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any medications for heart disease or high blood pressure.

Cichorium Intybus Whole must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of their predicted value are at an unacceptable risk for fatal bronchospasm during a reaction.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The heart may not be stable enough to survive the stress of anaphylaxis or the administration of emergency epinephrine.
3. 3History of Severe Anaphylaxis to Chicory: If a patient has previously had a life-threatening reaction to a very small amount of chicory, the risk of further testing or treatment may outweigh any possible benefit.
4. 4Inability to Receive Epinephrine: If a patient has a medical condition that makes the use of epinephrine impossible (e.g., certain severe arrhythmias), they cannot safely receive allergenic extracts.

These conditions require a careful risk-benefit analysis by the healthcare provider:

• Beta-Blocker Therapy: As discussed, this makes treating reactions difficult. If the beta-blocker cannot be stopped, immunotherapy is usually avoided.
• Pregnancy (Initiation): Immunotherapy should generally not be started during pregnancy due to the risk of anaphylaxis causing fetal hypoxia (lack of oxygen). However, if a patient is already on a stable maintenance dose, they may often continue.
• Autoimmune Disorders: There is a theoretical risk that stimulating the immune system with extracts could worsen certain autoimmune conditions, though data on this is limited.
• Malignancy: Patients with active cancer may have altered immune systems that make the response to immunotherapy unpredictable.

Patients who are allergic to Cichorium Intybus Whole often show cross-sensitivity to other members of the Asteraceae family. This includes:

• Ragweed (Ambrosia)
• Dandelion (Taraxacum)
• Chrysanthemums
• Sunflowers
• Echinacea

If you have had a severe reaction to any of these plants, you must inform your doctor before being tested with Cichorium Intybus Whole.

> Important: Your healthcare provider will evaluate your complete medical history, including your current lung function and heart health, before prescribing Cichorium Intybus Whole.

Cichorium Intybus Whole is classified as Pregnancy Category C. This means there are no adequate and well-controlled studies in pregnant women.

• Teratogenicity: There is no evidence that chicory allergens cause birth defects.
• Risks: The primary risk to the fetus is maternal anaphylaxis. A severe drop in the mother's blood pressure or a lack of oxygen during a reaction can lead to fetal distress, miscarriage, or premature labor.
• Clinical Guidance: Allergists generally do not start new immunotherapy or perform skin testing during pregnancy. If a woman becomes pregnant while on a maintenance dose that she is tolerating well, the treatment is usually continued at that dose without further increases.

It is generally considered safe to continue Cichorium Intybus Whole immunotherapy while breastfeeding. The allergenic proteins are broken down locally and are unlikely to pass into breast milk in any significant or harmful quantity. There is no evidence of adverse effects on the nursing infant. However, the mother should be monitored for systemic reactions as usual.

Cichorium Intybus Whole is used in the pediatric population, primarily for children aged 5 and older.

• Safety: The risk of systemic reactions in children is similar to that in adults. However, younger children may not be able to articulate the early 'aura' of an allergic reaction (such as an itchy throat or a sense of doom).
• Growth Effects: There are no known effects on growth or development from the use of allergenic extracts.
• Conditions: It is not approved for use in infants. The decision to use it in children under 5 is made on a case-by-case basis for severe allergies.

Elderly patients (over 65) require special consideration:

• Cardiovascular Reserve: Older adults are more likely to have undiagnosed coronary artery disease, which increases the risk of a heart attack during a systemic reaction.
• Polypharmacy: The higher likelihood of being on beta-blockers or ACE inhibitors increases the complexity of treatment.
• Renal Function: While not a direct concern for the extract, the clearance of other medications used to treat reactions may be slower.

There are no specific guidelines for Cichorium Intybus Whole in renal impairment. Because the extract is a biological protein that is degraded into amino acids, it does not accumulate in the blood in the same way as synthetic drugs. No dose adjustments are typically required for GFR changes, though the patient should be in stable health.

Liver disease does not affect the metabolism or safety of Cichorium Intybus Whole. The extract does not undergo hepatic metabolism. However, patients with severe liver failure (Child-Pugh Class C) may have coagulopathies (bleeding issues) that could make injections or skin testing more difficult due to bruising.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health problems during the course of your treatment.

Cichorium Intybus Whole acts as an immunomodulator. In the diagnostic phase, it acts as an antigen that cross-links IgE molecules on the surface of mast cells and basophils. This cross-linking triggers a signal transduction pathway involving tyrosine kinases (like Syk), leading to the release of pre-formed mediators (histamine) and the synthesis of new mediators (prostaglandins).

In the therapeutic phase (immunotherapy), the mechanism is more complex. It involves:

1. 1Desensitization: Early reduction in mast cell and basophil reactivity.
2. 2T-cell Tolerance: Induction of regulatory T-cells (Tregs) that produce IL-10 and TGF-beta, which suppress allergic inflammation.
3. 3Antibody Shift: A decrease in allergen-specific IgE and a significant increase in allergen-specific IgG4, which acts as a 'blocking antibody' to prevent IgE-antigen binding.

• Dose-Response: There is a clear dose-response relationship in skin testing; higher concentrations produce larger wheals. In immunotherapy, higher maintenance doses are generally more effective but carry a higher risk of side effects.
• Onset: Skin test reactions occur within 15-20 minutes. The therapeutic effect of immunotherapy takes months to develop, with significant symptom reduction usually seen after 6-12 months of treatment.
• Duration: The diagnostic effect is transient. The therapeutic effect can last for several years after the 3-5 year course of treatment is completed.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/Subcutaneous administration) |

| Protein Binding | N/A (Biological proteins) |

| Half-life | Varies by protein (minutes to hours for absorption) |

| Tmax | 15-30 minutes (for local reaction) |

| Metabolism | Proteolysis (Breakdown by proteases) |

| Excretion | Renal (as small peptides/amino acids) |

• Composition: A complex mixture of proteins (including sesquiterpene lactones), carbohydrates, and glycoproteins.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various allergenic fractions.
• Solubility: Soluble in aqueous solutions and 50% glycerin/water mixtures.
• Source: Derived from the whole plant of Cichorium intybus.

Cichorium Intybus Whole is classified as a Non-Standardized Plant Allergenic Extract. It is grouped with other Compositae family extracts such as Ragweed, Mugwort, and Dandelion. Unlike 'Standardized' extracts (like Grass or Dust Mite), its potency is not validated against a standard reference serum in the US, but rather by its manufacturing process (w/v).